Dcgi

Showing of 1 - 20 from 42 results
Dcgi - Total results - 42
CDSCO asks Bharat Biotech to submit complete immunogenicity data of Phase 2 trial of COVID-19 vaccine
India

CDSCO asks Bharat Biotech to submit complete immunogenicity data of Phase 2 trial of COVID-19 vaccine

The vaccine candidate, 'Covaxin', is being indigenously developed by Bharat Biotech in collaboration with the Indian Council of Medical Research

Dr Reddy's asked to resubmit phase 2,3 trial application for Russia's Sputnik V COVID-19 vaccine by DCGI
India

Dr Reddy's asked to resubmit phase 2,3 trial application for Russia's Sputnik V COVID-19 vaccine by DCGI

Dr Reddy's trials will have to be first assessed in a small group of volunteers to study its efficacy before it can be tested on a larger population.

ICMR gets DCGI nod to conduct clinical trials on humans for new COVID-19 treatment 'Antisera'
India

ICMR gets DCGI nod to conduct clinical trials on humans for new COVID-19 treatment 'Antisera'

Antisera are blood serum high in antibodies against specific antigens and are injected in humans to help kickstart the immune system to fight specific infections.

COVID-19 treatment: DCGI gives nod to Phase-1 human trials of 'antisera' therapy
Health

COVID-19 treatment: DCGI gives nod to Phase-1 human trials of 'antisera' therapy

Antisera are blood serum high in antibodies against specific antigens and are injected in humans to help kickstart the immune system to fight specific infections

DCGI shares draft guidelines for pharma giants manufacturing, distributing COVID-19 vaccines
India

DCGI shares draft guidelines for pharma giants manufacturing, distributing COVID-19 vaccines

Dr Balram Bhargava, Director-General of ICMR said, "There are three things for a vaccine--(i) the safety, (ii) immunogenicity, and (iii) the efficacy."

DCGI approves commercial launch of Tata Group's low-cost COVID-19 test 'Feluda'
India

DCGI approves commercial launch of Tata Group's low-cost COVID-19 test 'Feluda'

This test uses an indigenously-developed, cutting-edge CRISPR technology for detecting the virus' genome sequence

India's COVID-19 tally surpasses 50 lakh with 90,123 new cases: AstraZeneca trials to resume
India

India's COVID-19 tally surpasses 50 lakh with 90,123 new cases: AstraZeneca trials to resume

The Serum Institute of India, which had paused phase 2 and phase 3 trials of the Oxford University's vaccine, received the go-ahead from the DCGI to resume the trials in India

Serum Institute of India gets DCGI's nod to resume clinical trial of Oxford COVID-19 vaccine
India

Serum Institute of India gets DCGI's nod to resume clinical trial of Oxford COVID-19 vaccine

SII has also been asked to submit to the DCGI's office details of medication used in accordance with the protocol for management of adverse events

Coronavirus Updates: Kolkata Police Commissioner Anuj Sharma tests positive for COVID-19, says report
India

Coronavirus Updates: Kolkata Police Commissioner Anuj Sharma tests positive for COVID-19, says report

Coronavirus Updates: Lok Sabha Speaker Om Birla on Thursday also said that 62 percent of the Parliament's operations have been "successfully" moved online will go "100 percent digital eventually"

Coronavirus Vaccine Tracker: Serum Institute of India pauses clinical trials after DCGI show-cause notice
Health

Coronavirus Vaccine Tracker: Serum Institute of India pauses clinical trials after DCGI show-cause notice

The Pune-based company said that it's reviewing the situation and pausing India trials of the COVID-19 vaccine candidate till AstraZeneca restarts the trials

Coronavirus Updates: 11,514 new COVID-19 cases in Maharashtra today; tally rises to 4,79,779
India

Coronavirus Updates: 11,514 new COVID-19 cases in Maharashtra today; tally rises to 4,79,779

Coronavirus LIVE Updates: The Maharashtra health department said that 11,514 COVID-19 cases and 316 deaths were reported in the state on Thursday. Total number of cases in the state is now at 4,79,779, including 1,46,305 active cases, 3,16,375 recovered and 16,792 deaths.

Lupin launches antiviral drug Favipiravir under the name Covihalt to treat mild to moderate COVID-19 infection
science

Lupin launches antiviral drug Favipiravir under the name Covihalt to treat mild to moderate COVID-19 infection

The Covihalt tablet will be available in 200 mg tablets in a strip of 10 and will cost Rs 49 per tablet in India.

Sunpharma launches Favipiravir tablet Fluguard to treat mild to moderate COVID-19 infections at Rs 35 per pill
science

Sunpharma launches Favipiravir tablet Fluguard to treat mild to moderate COVID-19 infections at Rs 35 per pill

Favipiravir is an antiviral drug that was originally made to treat influenza in Japan under the brand name Avigan.

Coronavirus Updates: Maharashtra reports 7,760 new cases, 300 deaths; tally rises to 4,57,956
India

Coronavirus Updates: Maharashtra reports 7,760 new cases, 300 deaths; tally rises to 4,57,956

Coronavirus Updates: As many as 2,326 patients recovered during the day, the state health department said, taking the total number of recoveries to over 2.99 lakh

Serum Institute asked to revise protocols for Phase 2, 3 trials of Oxford COVID-19 vaccine candidate
science

Serum Institute asked to revise protocols for Phase 2, 3 trials of Oxford COVID-19 vaccine candidate

The CDSCO expert panel also recommended that Pune-based firm's proposed clinical trial sites be distributed across India

Drugs body CDSCO suspends import licences of 19 firms for non-USFDA COVID-19 testing kits
India

Drugs body CDSCO suspends import licences of 19 firms for non-USFDA COVID-19 testing kits

The decision was taken after the drug controller found the companies' response to a 17 July show-cause notice asking them to explain why their licences should not be suspended unsatisfactory

AIIMS panel gives nod to begin human clinical trial of COVID-19 vaccine Covaxin from 20 July
India

AIIMS panel gives nod to begin human clinical trial of COVID-19 vaccine Covaxin from 20 July

Covaxin, Bharat Biotech's COVID-19 vaccine candidate, has been developed in collaboration with the ICMR and NIV

India's first indigenous pneumonia vaccine developed by Serum Institute get DCGI nod for market
science

India's first indigenous pneumonia vaccine developed by Serum Institute get DCGI nod for market

Serum Institute conducted a three-phase clinical trial of the vaccine in India along with trials in the West African nation of The Gambia.

DCGI approves psoriasis injection for 'restricted emergency use' to treat COVID-19 patients
India

DCGI approves psoriasis injection for 'restricted emergency use' to treat COVID-19 patients

Drugs Controller General of India approved monoclonal antibody injection Itolizumab for limited use to treat moderate to severe cases of COVID-19.

Indian pharma well-placed to develop, manufacture COVID-19 vaccine; but it must guard against rushing trials
India

Indian pharma well-placed to develop, manufacture COVID-19 vaccine; but it must guard against rushing trials

Some experts told Firstpost that the government is willing to fast-track regulation, which is a risk they are willing to take, after completing "due protocols to check the safety of the drug"